Galmed Pharmaceuticals LtdNASDAQ:GLMD
- LAST PRICE2.9300
- TODAY'S CHANGE (%)-0.1700 (-5.4839%)
- Bid / Lots2.8500/ 1
- Ask / Lots3.0000/ 2
- Open / Previous Close3.0300 / 3.1000
- Day Range
- 52 Week Range
- Volume35,563
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GLMD |
|---|---|---|
| 09:32 ET | 5235 | 3 |
| 09:33 ET | 3000 | 2.98 |
| 09:37 ET | 321 | 2.99 |
| 09:44 ET | 120 | 3 |
| 09:48 ET | 448 | 2.933662 |
| 09:50 ET | 200 | 2.9843 |
| 09:57 ET | 4100 | 3 |
| 10:04 ET | 100 | 2.97 |
| 10:08 ET | 200 | 2.99 |
| 10:11 ET | 167 | 3.12 |
| 10:27 ET | 100 | 2.9585 |
| 10:33 ET | 1300 | 3.085 |
| 10:38 ET | 500 | 2.97 |
| 11:07 ET | 2529 | 2.9 |
| 11:16 ET | 300 | 2.9943 |
| 11:36 ET | 300 | 2.95 |
| 11:45 ET | 1213 | 2.94 |
| 11:54 ET | 250 | 2.95 |
| 12:10 ET | 1975 | 2.88 |
| 12:35 ET | 200 | 2.9506 |
| 12:42 ET | 200 | 2.9 |
| 12:51 ET | 888 | 2.95 |
| 12:53 ET | 1004 | 2.95 |
| 12:57 ET | 100 | 2.9 |
| 01:26 ET | 1478 | 2.9 |
| 02:03 ET | 161 | 2.967 |
| 02:05 ET | 1000 | 2.901 |
| 02:18 ET | 500 | 2.88 |
| 02:41 ET | 200 | 2.8875 |
| 04:00 ET | 1596 | 2.93 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Galmed Pharmaceuticals Ltd | 4.4M | -0.1x | --- |
NuCana PLC | 3.4M | 0.0x | --- |
Check Cap Ltd | 4.5M | -0.3x | --- |
Portage Biotech Inc | 4.3M | -0.1x | --- |
Pasithea Therapeutics Corp | 4.3M | -0.2x | --- |
Weed Inc | 4.5M | 70.8x | --- |
Company Information
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
Contact Information
- Headquarters
- 16 Tiomkin StreetTEL AVIV-YAFO, Israel 6578317
- Phone
- ---
- Fax
- ---
Executives
- President, Chief Executive Officer, Director
- Allen Baharaff
- Chief Financial Officer
- Doron Cohen
- Chief Operating Officer, Data Protection Officer
- Guy Nehemya
- Chief Accounting Officer
- Yohai Stenzler
- Chief Scientific Officer
- Liat Hayardeny
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.77 |
EPS | $-24.68 |
Book Value | $33.01 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
